R Squared’s Cabaletta Bio CABA Stock Holding History

R Squared’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-380	Closed	-$863	–	492
2024 Q4	$863	Buy	+380	New	+$1.33K	﹤0.01%	1520

Other funds holding CABA

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R Squared's CABA Position: Q1 2025 in Review

R Squared sold out of Cabaletta Bio (CABA) in Q1 2025, closing a stake of 380 shares — an estimated $863 sold.

R Squared first reported a position in CABA in Q4 2024 and held it in 1 quarter. The position peaked at $863 in Q4 2024. 92 funds tracked by Wall St. Rank hold CABA as of Q1 2025.

R Squared reported no remaining Cabaletta Bio position as of Q1 2025 after selling out during the quarter.
R Squared sold 380 Cabaletta Bio shares in Q1 2025, an estimated $863.
R Squared first reported a position in Cabaletta Bio in Q4 2024 and held it in 1 quarter.
R Squared's Cabaletta Bio position peaked at $863 in Q4 2024.
92 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.